<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1452">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05142254</url>
  </required_header>
  <id_info>
    <org_study_id>202504</org_study_id>
    <nct_id>NCT05142254</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Double-Blind Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study</brief_title>
  <acronym>PIN</acronym>
  <official_title>A Randomized Controlled Double-Blind Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To conduct a randomized controlled internal pilot feasibility trial for the prevention of&#xD;
      recurrent ischemic priapism referred to as the Priapism in Nigeria (PIN) trial. The study&#xD;
      team will enroll a minimum of 30 participants and a maximum of 200 participants. Study&#xD;
      investigators hypothesize that hydroxyurea therapy combined with tadalafil is superior to a&#xD;
      combination of hydroxyurea and placebo in the prevention of recurrent ischemic priapism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sickle cell disease (SCD) is one of the commonest genetic diseases in the world.&#xD;
      Approximately 300,000 newborns are born with SCD every year, with 50% of the birth being in&#xD;
      Nigeria alone.(1) This huge burden makes Nigeria critical to any intervention that seeks to&#xD;
      address the challenges of individuals with SCD. Men with SCD experience many complications,&#xD;
      which can even affect their sexuality and reproductive health.(13) One of the most common,&#xD;
      but often neglected complications of SCD in men is priapism. Priapism is defined as a&#xD;
      painful, purposeless, and sustained erection.(3,8) In men with SCD, priapism tends to be&#xD;
      recurrent and devastating.(14) The prevalence of priapism was 42% in Jamaican men with&#xD;
      SCD.(15) Serjeant et al. reported the incidence of priapism in SCD to be very low before the&#xD;
      age of 10 years, but the cumulative incidence rose to 32.7% by the age of 20 years.(16)&#xD;
      Adeyoju et al. reported the prevalence of priapism in SCD to be 35%, out of which 72% was&#xD;
      recurrent ischemic priapism (lasting &lt;4 hours).(14) The majority of the individuals with SCD&#xD;
      experienced their first episode of priapism before the age of 20 years, with a mean age of&#xD;
      onset being 15 years.(14) In a cross-sectional study of 353 men with SCD, conducted by our&#xD;
      team in Kano, Nigeria, the prevalence of priapism was approximately 32%; out of which 74% was&#xD;
      recurrent ischemic priapism (unpublished). In the same study, the prevalence of priapism in&#xD;
      men without SCD (n=250) was 2%. The results from focus groups (3 in Nigeria and 3 in the&#xD;
      U.S.) our team conducted revealed men with SCD who experienced recurrent ischemic priapism&#xD;
      struggled with embarrassment, shame, anxiety and depression, and declining sexual function&#xD;
      (unpublished).&#xD;
&#xD;
      The prevention and treatment of ischemic priapism in SCD is still inadequate. Virag et al.&#xD;
      used a combination of preventive oral etilefrine and self-administered intracavernosal&#xD;
      injection of etilefrine for breakthrough priapism lasting &gt;1 hour. Sixty-six percent (4 of 6)&#xD;
      had no recurrence of priapism while the remaining two used intracavernosal injection of&#xD;
      etilefrine.(20) In a non-RCT study, Okpala et al. reported a good response to oral&#xD;
      etilefrine; which was shown to have reduced the frequency of recurrent ischemic priapism in&#xD;
      SCD (mean difference 5.78); P &lt; 0.0001.(21) However, in the only RCT for this drug,&#xD;
      etilefrine was found to have no efficacy over placebo.(22) Daibes et al. showed that in 35&#xD;
      patients on graded doses of finasteride (5-alpha reductase inhibitor), priapism recurrences&#xD;
      were reduced from an average of 22.7 to 2.1 at the end of the 120-day follow-up.(23) A&#xD;
      combination of oral ketoconazole with prednisolone showed a promising result in case-series&#xD;
      reported by Abern et al.(24) However, an RCT (n=40) showed no efficacy of ketoconazole&#xD;
      (81.25% and 83% in both arms still having post-operative painful erections).(25) In another&#xD;
      study by Saad et al., hydroxyurea was shown to have decreased priapism recurrences in 4 of 5&#xD;
      men treated with a high dose.(26) Nonetheless, stopping hydroxyurea heralded relapse of&#xD;
      priapism. Burnett et al. reported that sildenafil has controlled priapism experiences in 6 of&#xD;
      7 men observed.(27) Non-RCT designs, small sample sizes, or adverse effects of the trial&#xD;
      medications limit most of these studies.&#xD;
&#xD;
      This conceptual framework is based on the synergistic effect of tadalafil (PDE-5 inhibitor,&#xD;
      which increases the bioavailability of cGMP),(7), and hydroxyurea (NO donor).(9) In SCD there&#xD;
      is chronic hemolysis causing depletion of NO and dysregulation of PDE-5, which underpin the&#xD;
      molecular basis of priapism. Chronic dosing of low-dose tadalafil inhibits PDE-5 to&#xD;
      paradoxically restore the normal homeostatic mechanism of the NO-cGMP-PDE-5 pathway. Restored&#xD;
      PDE-5 function helps prevent recurrent ischemic priapism.&#xD;
&#xD;
      Despite the need, all prior priapism studies did not provide sufficient evidence for&#xD;
      practice-based outcomes. Several reasons exist for the lack of any substantial progress for&#xD;
      secondary prevention of ischemic priapism, the foremost of which is that SCD is a rare&#xD;
      disease in high-income settings where most of the studies have been conducted. To overcome&#xD;
      these limitations, the investigators propose an internal pilot trial to assess the&#xD;
      feasibility trial in a setting where there are over 5000 men available to be enrolled in one&#xD;
      city, Kano Nigeria. The trial will also build on the infrastructures and workflow established&#xD;
      by NIH-funded pre-existing SCD stroke prevention trials conducted at the same hospitals in&#xD;
      Kano.&#xD;
&#xD;
      The aims are 1) To conduct a randomized internal pilot trial and possible complete a phase&#xD;
      III trial for the prevention of recurrent ischemic priapism (hydroxyurea + tadalafil vs&#xD;
      hydroxyurea + placebo), referred to as the Priapism in Nigeria (PIN) trial, and 2) To assess&#xD;
      the tolerability of moderate-dose hydroxyurea and its effect on spermatogenesis.&#xD;
&#xD;
      Trained study personnel will approach the eligible participants for consenting. After&#xD;
      obtaining signed informed consent and ensuring they have fulfilled inclusion criteria, the&#xD;
      participants will be randomized 1:1 to the treatment and placebo arms. The primary study&#xD;
      statistician will be supported by a local statistician in Nigeria to perform the&#xD;
      randomization process. After the random allocation, all study personnel and participants will&#xD;
      be blinded to the treatment. The treatment arm will include tadalafil, given orally initially&#xD;
      at a low-dose of 2.5 mg daily for four weeks. If tolerated very well during the four weeks,&#xD;
      the dose will be increased to 5.0 mg daily as the final dose. Tadalafil and the identical&#xD;
      placebo will be purchased from a local pharmaceutical company, Bond Chemical Nigerian&#xD;
      Limited, which is licensed to produce tadalafil and hydroxyurea in Nigeria. Participants will&#xD;
      be instructed to take tadalafil or placebo in the morning for this trial. Chronic morning&#xD;
      dosing with tadalafil will allow the drug to be metabolized and is unlikely to be associated&#xD;
      with sleep-related erections. Both treatment and placebo arms will be on hydroxyurea as&#xD;
      standard care. Hydroxyurea will be given orally at a moderate-dose of 20mg/kg/day and is also&#xD;
      produced by the Bond Chemical Nigerian Limited. The moderate-dose of hydroxyurea is found to&#xD;
      be effective, with minimal adverse effects, in the preliminary data of stroke prevention in&#xD;
      Nigeria (1R01NS094041) trial just recently completed in Kano, Nigeria. Both arms of the trial&#xD;
      will be followed for one year; afterward, the trial will go into the open-label phase. The&#xD;
      participant can select whether they want to continue either therapy or start a new treatment.&#xD;
      At the baseline, demographic and clinical data from medical records of the participants will&#xD;
      be collected. The data will include but are not limited to: co-morbidities (hypertension,&#xD;
      diabetes, etc.), drug history (antihypertensives, aphrodisiacs, hormonal shots, alpha&#xD;
      receptor agonists, antipsychotics, etc.), pain history, and blood transfusions history. The&#xD;
      investigators will use internationally validated questionnaires (International Index of&#xD;
      Erectile Function [IIEF],(24) PROMIS Erectile function,(25) sexual activity, and satisfaction&#xD;
      with sex life) to evaluate erectile and sexual functions of the participants at baseline and&#xD;
      subsequent follow-ups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Double-Blind Trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The primary study statistician will be supported by a local statistician in Nigeria to perform the randomization process. After the random allocation, all study personnel and participants will be blinded to the treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>A reduction in the recurrence rate of priapism</measure>
    <time_frame>Within a year, we will measure recurrence rates</time_frame>
    <description>We will use negative binomial regression to calculate the hazard rate for rate of priapism recurrence in both arms and determine whether there is a difference in recurrence between the two arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The rate of vaso-occlusive pain, including hospitalizations</measure>
    <time_frame>Baseline- one year</time_frame>
    <description>We will use a non-parametric test (Mann Whitney U) and negative binomial regression to compare hospitalizations for acute pain between the 2 arms of the trial, controlling for age and other baseline characteristics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of erectile and sexual functions</measure>
    <time_frame>Baseline- one year</time_frame>
    <description>International Index of Erectile Function (IIEF) Survey- 15 questions on a scale from 0 to 5. The survey examines 4 main domains of male sexual function and overall satisfaction. The maximum total score for the survey is 75, with each domain having a maximum score of 30, 10, 10, 15, and 10 respectively . Scores below 14 in the first domain (out of 30) indicate erectile function issues.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of erectile and sexual functions</measure>
    <time_frame>Baseline- one year</time_frame>
    <description>Promis Bank V20 Satisfaction With Sex Life (5 total questions, ranging from not at all to very and various iterations- total score will be taken and compared to PROMIS standards)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of erectile and sexual functions</measure>
    <time_frame>Baseline- one year</time_frame>
    <description>Testosterone Levels- measured in ng/dL (normal range 265-923 ng/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of erectile and sexual functions</measure>
    <time_frame>Baseline- one year</time_frame>
    <description>FSH Levels- measured in mIU/mL (normal range 1.5-12.4 mIU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of erectile and sexual functions</measure>
    <time_frame>Baseline- one year</time_frame>
    <description>LH Levels- measured in IU/L (normal range 1.8-8.6 IU/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of erectile and sexual functions</measure>
    <time_frame>Baseline- one year</time_frame>
    <description>Prolactin Levels- measured in ng/mL (normal range &lt;20 ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of erectile and sexual functions</measure>
    <time_frame>Baseline- one year</time_frame>
    <description>Promise Bank V20 Erectile Function (11 total questions, ranging from almost never/never to almost always/always and various iterations-total score will be taken and compared to PROMIS standards)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of erectile and sexual functions</measure>
    <time_frame>Baseline- one year</time_frame>
    <description>Promis Scale V20 Interest In Sexual Activity (2 total questions ranging from not at all to very and never to always- total score will be taken and compared to PROMIS standards)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of erectile and sexual functions</measure>
    <time_frame>Baseline- one year</time_frame>
    <description>Promis 29 Profile V20 (29 total questions, ranging from not at all to very much and never to always- total score will be taken and compared to PROMIS standards)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Priapism Due to Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Tadalafil and Hydroxyurea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tadalafil 2.5-5 mg/day and Hydroxyurea 20 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Hydroxyurea</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and Hydroxyurea 20 mg/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>2.5-5 mg/day</description>
    <arm_group_label>Tadalafil and Hydroxyurea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea</intervention_name>
    <description>20 mg/kg/day</description>
    <arm_group_label>Placebo and Hydroxyurea</arm_group_label>
    <arm_group_label>Tadalafil and Hydroxyurea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>identical placebo to tadalafil created by Bond Biochemical, who is manufacturing the tadalafil as well.</description>
    <arm_group_label>Placebo and Hydroxyurea</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men with confirmed diagnosis of HbSS or Hb beta zero thalassemia&#xD;
&#xD;
          -  Ages between 18 to 40 years&#xD;
&#xD;
          -  Eligible study participants must receive care in an SCD clinic at AKTH and MMSH at the&#xD;
             time of the recruitment&#xD;
&#xD;
          -  Participants must commit to long-term follow-up and taking the trial medications&#xD;
&#xD;
          -  At least 3 episodes of priapism, each lasting for no less than an hour in the past 6&#xD;
             months.&#xD;
&#xD;
          -  Adequate renal and hepatic function (baseline liver enzymes and synthetic activities&#xD;
             should be no more than four-fold above the reference ranges for Aminu Kano Teaching&#xD;
             Hospital (AKTH). These are the ranges obtained in AKTH: Alkaline phosphatase: 42-110&#xD;
             U/L, Alanine transaminase: 4-34 U/L, Aspartate transaminase: 7-45 U/L, Albumin: 32-52&#xD;
             g/L, and Globulin: 32-43 g/L.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals already enrolled in another clinical trial&#xD;
&#xD;
          -  eGFR &lt;50ml/min&#xD;
&#xD;
          -  Liver cirrhosis based on clinical history, laboratory data or both&#xD;
&#xD;
          -  Previously known pulmonary hypertension based on TRJV greater than 3.0 m/sec&#xD;
&#xD;
          -  Contraindications to tadalafil (arrhythmia, severe liver disease, concurrent use of&#xD;
             nitrates, etc.) or hydroxyurea (leg ulcer, hypersensitivity, etc.).&#xD;
&#xD;
          -  Patients who have penile prosthetic implants or shunts or any other surgical procedure&#xD;
             on the penis&#xD;
&#xD;
          -  Patients who have taken drugs/medications that may induce priapism over the 14 weeks&#xD;
             before trial:&#xD;
&#xD;
          -  Medications injected directly into the penis to treat erectile dysfunction, such as&#xD;
             alprostadil, papaverine, phentolamine, and others&#xD;
&#xD;
          -  Antidepressants, such as fluoxetine, bupropion, and sertraline&#xD;
&#xD;
          -  Alpha blockers including prazosin, terazosin, doxazosin, and tamsulosin&#xD;
&#xD;
          -  Medications used to treat anxiety or psychotic disorders, such as hydroxyzine,&#xD;
             risperidone, olanzapine, lithium, clozapine, chlorpromazine, and thioridazine&#xD;
&#xD;
          -  Blood thinners, such as warfarin and heparin&#xD;
&#xD;
          -  Hormones such as testosterone or gonadotropin-releasing hormone&#xD;
&#xD;
          -  Medications used to treat attention-deficit/hyperactivity disorder (ADHD), such as&#xD;
             atomoxetine (Strattera)&#xD;
&#xD;
          -  Alcohol, marijuana, cocaine and other illicit drug abuse can cause priapism&#xD;
&#xD;
          -  Not able to understand or comply with study instructions and requirements&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leshana St. Jean, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael DeBaun, MD, MPH</last_name>
    <phone>615-875-3040</phone>
    <email>m.debaun@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maya Chopra, BA</last_name>
    <phone>614-915-6974</phone>
    <email>maya.chopra.1@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aminu Kano Teaching Hospital</name>
      <address>
        <city>Kano</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <contact>
      <last_name>Ibrahim Musa Idris, MBBS, MPH</last_name>
      <phone>234-8039685753</phone>
      <email>muazamusa@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Bilya Sani Musa, BSc, CCRP</last_name>
      <phone>234-8036005052</phone>
      <email>bilyasani@yahoo.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Murtala Mohammed Specialist Hospital</name>
      <address>
        <city>Kano</city>
        <country>Nigeria</country>
      </address>
    </facility>
    <contact>
      <last_name>Jamil Galadanci, MSc</last_name>
      <phone>234-8035993379</phone>
      <email>jamilgaladanci@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Nigeria</country>
  </location_countries>
  <reference>
    <citation>Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10(7):e1001484. doi: 10.1371/journal.pmed.1001484. Epub 2013 Jul 16.</citation>
    <PMID>23874164</PMID>
  </reference>
  <reference>
    <citation>Anele UA, Morrison BF, Burnett AL. Molecular pathophysiology of priapism: emerging targets. Curr Drug Targets. 2015;16(5):474-83. Review.</citation>
    <PMID>25392014</PMID>
  </reference>
  <reference>
    <citation>Huang AW, Muneyyirci-Delale O. Reproductive endocrine issues in men with sickle cell anemia. Andrology. 2017 Jul;5(4):679-690. doi: 10.1111/andr.12370. Epub 2017 Jun 29. Review.</citation>
    <PMID>28662541</PMID>
  </reference>
  <reference>
    <citation>Adeyoju AB, Olujohungbe AB, Morris J, Yardumian A, Bareford D, Akenova A, Akinyanju O, Cinkotai K, O'Reilly PH. Priapism in sickle-cell disease; incidence, risk factors and complications - an international multicentre study. BJU Int. 2002 Dec;90(9):898-902.</citation>
    <PMID>12460353</PMID>
  </reference>
  <reference>
    <citation>Emond AM, Holman R, Hayes RJ, Serjeant GR. Priapism and impotence in homozygous sickle cell disease. Arch Intern Med. 1980 Nov;140(11):1434-7.</citation>
    <PMID>6159833</PMID>
  </reference>
  <reference>
    <citation>Serjeant G, Hambleton I. Priapism in Homozygous Sickle Cell Disease: A 40-year Study of the Natural History. West Indian Med J. 2015 Jun;64(3):175-80. doi: 10.7727/wimj.2014.119. Epub 2015 Apr 27.</citation>
    <PMID>26426165</PMID>
  </reference>
  <reference>
    <citation>Virag R, Bachir D, Lee K, Galacteros F. Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine. Urology. 1996 May;47(5):777-81; discussion 781.</citation>
    <PMID>8650886</PMID>
  </reference>
  <reference>
    <citation>Okpala I, Westerdale N, Jegede T, Cheung B. Etilefrine for the prevention of priapism in adult sickle cell disease. Br J Haematol. 2002 Sep;118(3):918-21.</citation>
    <PMID>12181066</PMID>
  </reference>
  <reference>
    <citation>Olujohungbe AB, Adeyoju A, Yardumian A, Akinyanju O, Morris J, Westerdale N, Akenova Y, Kehinde MO, Anie K, Howard J, Brooks A, Davis VA, Khoriatry AI. A prospective diary study of stuttering priapism in adolescents and young men with sickle cell anemia: report of an international randomized control trial--the priapism in sickle cell study. J Androl. 2011 Jul-Aug;32(4):375-82. doi: 10.2164/jandrol.110.010934. Epub 2010 Dec 2.</citation>
    <PMID>21127308</PMID>
  </reference>
  <reference>
    <citation>Rachid-Filho D, Cavalcanti AG, Favorito LA, Costa WS, Sampaio FJ. Treatment of recurrent priapism in sickle cell anemia with finasteride: a new approach. Urology. 2009 Nov;74(5):1054-7. doi: 10.1016/j.urology.2009.04.071. Epub 2009 Jul 17.</citation>
    <PMID>19616292</PMID>
  </reference>
  <reference>
    <citation>Abern MR, Levine LA. Ketoconazole and prednisone to prevent recurrent ischemic priapism. J Urol. 2009 Oct;182(4):1401-6. doi: 10.1016/j.juro.2009.06.040. Epub 2009 Aug 15.</citation>
    <PMID>19683289</PMID>
  </reference>
  <reference>
    <citation>DeCastro BJ, Costabile RA, McMann LP, Peterson AC. Oral ketoconazole for prevention of postoperative penile erection: a placebo controlled, randomized, double-blind trial. J Urol. 2008 May;179(5):1930-2. doi: 10.1016/j.juro.2008.01.039. Epub 2008 Mar 18.</citation>
    <PMID>18353393</PMID>
  </reference>
  <reference>
    <citation>Saad ST, Lajolo C, Gilli S, Marques JÃºnior JF, Lima CS, Costa FF, Arruda VR. Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. Am J Hematol. 2004 Sep;77(1):45-9.</citation>
    <PMID>15307105</PMID>
  </reference>
  <reference>
    <citation>Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med. 2006 Nov;3(6):1077-1084. doi: 10.1111/j.1743-6109.2006.00333.x.</citation>
    <PMID>17100941</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Michael DeBaun</investigator_full_name>
    <investigator_title>M.D. MPH, Director Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Priapism</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyurea</mesh_term>
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

